The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations

 

 Permissions and Reprints

Abstract

The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives that tailor interventions to the needs of these populations. Micro-elimination is less daunting, less complex, and less costly than full-scale, country-level initiatives to eliminate HCV, and it can build momentum by producing small victories that inspire more ambitious efforts. The micro-elimination approach encourages stakeholders who are most knowledgeable about specific populations to engage with each other and also promotes the uptake of new models of care. Examples of micro-elimination target populations include medical patients, people who inject drugs, migrants, and prisoners, although candidate populations can be expected to vary greatly in different countries and subnational areas.

• References

• 1 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2 (03) 161-176
  PubMedGoogle Scholar
• 2 World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 3 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385 (9963): 117-171
  CrossrefPubMedGoogle Scholar
• 4 World Health Organization. Global Health Sector Strategy on Viral Hepatitis, 2016–2021: Towards Ending Viral Hepatitis. Geneva: World Health Organization. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 5 World Health Organization. Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low- and Middle-Income Countries. Geneva: World Health Organization. 2018. http://apps.who.int/iris/handle/10665/260445 . Accessed April 26, 2018
  PubMedGoogle Scholar
• 6 The Polaris Observatory. News. Available at: http://cdafound.org/news/ . Accessed June 27, 2018
  PubMedGoogle Scholar
• 7 Lazarus JV, Wiktor S, Colombo M, Thursz M. ; EASL International Liver Foundation. Micro-elimination - a path to global elimination of hepatitis C. J Hepatol 2017; 67 (04) 665-666
  CrossrefPubMedGoogle Scholar
• 8 The Polaris Observatory. Untitled. Available at: http://cdafound.org/polaris/ . Accessed June 27, 2018
  PubMed
• 9 Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60 (17) 537-541
  PubMedGoogle Scholar
• 10 Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth - Tennessee and United States, 2009-2014. MMWR Morb Mortal Wkly Rep 2017; 66 (18) 470-473
  CrossrefPubMedGoogle Scholar
• 11 Office of the United Nations High Commissioner for Human Rights. Frequently Asked Questions on Economic, Social and Cultural Rights: Fact Sheet No. 33. 2008. Available at: http://www.ohchr.org/Documents/Publications/FactSheet33en.pdf
  PubMedGoogle Scholar
• 12 Lazarus JV, Pericàs JM, Hetherington KL. Micro-elimination – a key component of global hepatitis C elimination. In: Hatzakis A, ed. Epidemiology, Prevention, Management and Elimination of Hepatitis C - Volume III Elimination of HCV. Springer; 2018. ( in press )
  Google Scholar
• 13 Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11 (01) 28-35
  CrossrefPubMedGoogle Scholar
• 14 Howard A, Stone K. The Global State of Harm Reduction 2016. London: Harm Reduction International; 2016. https://www.hri.global/files/2016/11/14/GSHR2016_14nov.pdf . Accessed 01 May 2018
  PubMedGoogle Scholar
• 15 Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013; 57 (Suppl. 02) S56-S61
  CrossrefPubMedGoogle Scholar
• 16 Tait JM, Wang H, Stephens BP. , et al. Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients. J Viral Hepat 2017; 24 (03) 207-215
  CrossrefPubMedGoogle Scholar
• 17 Radley A, Melville K, Tait J, Stephens B, Evans JMM, Dillon JF. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. Frontline Gastroenterol 2017; 8 (03) 221-228
  CrossrefPubMedGoogle Scholar
• 18 Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Int J Drug Policy 2017; 47: 126-136
  CrossrefPubMedGoogle Scholar
• 19 Mathur P, Comstock E, McSweegan E, Mercer N, Kumar NS, Kottilil S. A pilot study to expand treatment of chronic hepatitis C in resource-limited settings. Antiviral Res 2017; 146: 184-190
  CrossrefPubMedGoogle Scholar
• 20 Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. Aliment Pharmacol Ther 2016; 44 (02) 145-156
  CrossrefPubMedGoogle Scholar
• 21 Fraser H, Martin NK, Brummer-Korvenkontio H. , et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 2018; 68 (03) 402-411
  CrossrefPubMedGoogle Scholar
• 22 Gountas I, Sypsa V, Anagnostou O. , et al. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. Addiction 2017; 112 (07) 1290-1299
  CrossrefPubMedGoogle Scholar
• 23 Ayoub HH, Abu-Raddad LJ. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: a case for treatment as prevention. J Viral Hepat 2017; 24 (06) 486-495
  CrossrefPubMedGoogle Scholar
• 24 Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 2015; 28 (06) 576-582
  CrossrefPubMedGoogle Scholar
• 25 Kirby Institute. Bloodborne Viral and Sexually Transmissible Infections in Aboriginal and Torres Strait Islander People: Annual Surveillance Report 2017. Sydney: Kirby Institute, UNSW Sydney; 2017. https://kirby.unsw.edu.au/sites/default/files/kirby/report/KirbyInst_Indigenous_ASR2017-compressed.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 26 United States Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States, 2015. Atlanta, GA: United States Centers for Disease Control and Prevention; 2017. https://www.cdc.gov/hepatitis/statistics/2015surveillance/pdfs/2015HepSurveillanceRpt.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 27 Parmar P, Corsi DJ, Cooper C. Distribution of hepatitis C risk factors and HCV treatment outcomes among Central Canadian Aboriginal. Can J Gastroenterol Hepatol 2016; 2016: 8987976
  PubMedGoogle Scholar
• 28 Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007: Final Report. Public Health Agency of Canada. http://www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf . Accessed 11 May 2018
  PubMedGoogle Scholar
• 29 Alvarado-Mora MV, Fernandez MFG, Gomes-Gouvêa MS, de Azevedo Neto RS, Carrilho FJ, Pinho JR. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation?. PLoS One 2011; 6 (04) e18888
  CrossrefPubMedGoogle Scholar
• 30 Maaroufi A, Vince A, Himatt SM. , et al. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017; 24 (Suppl. 02) 8-24
  CrossrefPubMedGoogle Scholar
• 31 Conway J, Tsourtos G, Lawn S. The barriers and facilitators that indigenous health workers experience in their workplace and communities in providing self-management support: a multiple case study. BMC Health Serv Res 2017; 17 (01) 319
  CrossrefPubMedGoogle Scholar
• 32 Marrone S. Understanding barriers to health care: a review of disparities in health care services among indigenous populations. Int J Circumpolar Health 2007; 66 (03) 188-198
  CrossrefPubMedGoogle Scholar
• 33 Gilliver R, Machin W, Kearley J, Lothian R, Chronister K, Read P. Treatment of Aboriginal and Torres Strait Islander Clients with Direct Acting Antivirals at the Kirketon Road Centre: An Integrated Primary Health Care Setting Serving Highly Marginalised Populations. Paper presented at the 11 Australasian Viral Hepatitis Elimination Conference (AVHEC), August 10–11, 2017, Cairns, Queensland, Australia. https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/4e0f10ee77634cc2a4a357984cd559d1 . Accessed April 26, 2018
  PubMedGoogle Scholar
• 34 Reilley B, Leston J, Hariri S. , et al. Birth cohort testing for hepatitis C virus — Indian Health Service 2012–2015. MMWR Morb Mortal Wkly Rep 2016; 65 (18) 467-469
  CrossrefPubMedGoogle Scholar
• 35 Mera J, Vellozzi C, Hariri S. , et al. Identification and clinical management of persons with chronic hepatitis C virus infection - Cherokee Nation, 2012–2015. MMWR Morb Mortal Wkly Rep 2016; 65 (18) 461-466
  PubMedGoogle Scholar
• 36 Chlibek R, Smetana J, Sosovickova R. , et al. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017; 12 (04) e0175525
  CrossrefPubMedGoogle Scholar
• 37 Baptista-González H, Noffal-Nuño VM, Méndez-Sánchez N. Frequency of hepatitis C virus infection in a single institution in Mexico with a focus on birth-cohort population. Ann Hepatol 2016; 15 (06) 846-852
  PubMedGoogle Scholar
• 38 Bruggmann P, Negro F, Bihl F. , et al. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly 2015; 145: w14221
  PubMedGoogle Scholar
• 39 Rosińska M, Parda N, Kołakowska A. , et al. Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: a cross-sectional study in the general population in Poland, 2012-2016. PLoS One 2017; 12 (09) e0185055
  CrossrefPubMedGoogle Scholar
• 40 Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infect Dis 2017; 17 (Suppl. 01) 697
  CrossrefPubMedGoogle Scholar
• 41 Heil J, Hoebe CJPA, Cals JWL, Ter Waarbeek HLG, van Loo IHM, Dukers-Muijrers NHTM. Detecting hepatitis B and C by combined public health and primary care birth cohort testing. Ann Fam Med 2018; 16 (01) 21-27
  CrossrefPubMedGoogle Scholar
• 42 Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59 (06) 765-773
  CrossrefPubMedGoogle Scholar
• 43 Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun 2017; 1 (02) 87-98
  CrossrefPubMedGoogle Scholar
• 44 Lagging M, Wejstål R, Duberg AS, Aleman S, Weiland O, Westin J. ; for the Swedish Consensus Group. Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infect Dis (Lond) 2018; ( e-pub ahead of print ) DOI: 10.1080/23744235.2018.1445281.
  PubMedGoogle Scholar
• 45 Towers CV, Fortner KB. Infant follow-up postdelivery from a hepatitis C viral load positive mother. J Matern Fetal Neonatal Med 2018; ( e-pub ahead of print ) DOI: 10.1080/14767058.2018.1458836.
  PubMedGoogle Scholar
• 46 World Health Organization. Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization; February 2017. http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf?ua=1 . Accessed May 10, 2018
  PubMedGoogle Scholar
• 47 Urbanus AT, van Keep M, Matser AA. , et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?. PLoS One 2013; 8 (08) e70319
  CrossrefPubMedGoogle Scholar
• 48 Jadoul M. The prevention of hepatitis C virus transmission to hemodialysis patients and staff members. Hemodial Int 2018; 22 (Suppl. 01) S104-S109
  CrossrefPubMedGoogle Scholar
• 49 Ko SY, Choe WH. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clin Mol Hepatol 2018; ( e-pub ahead of print ) DOI: 10.3350/cmh.2017.0063.
  PubMedGoogle Scholar
• 50 Komitova RT, Atanasova MV, Pavlova TA, Nyagolov MS, Ivanova AV. Diagnostic dilemmas in hepatitis C virus infection for hemodialysis patients. Folia Med (Plovdiv) 2017; 59 (01) 70-77
  PubMedGoogle Scholar
• 51 Carvalho-Filho RJ, Feldner AC, Silva AE, Ferraz ML. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015; 21 (02) 408-422
  CrossrefPubMedGoogle Scholar
• 52 Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol 2017; 12 (02) 287-297
  CrossrefPubMedGoogle Scholar
• 53 Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol 2015; 7 (01) 78-92
  CrossrefPubMedGoogle Scholar
• 54 Gane E, Lawitz E, Pugatch D. , et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017; 377 (15) 1448-1455
  CrossrefPubMedGoogle Scholar
• 55 Taneja S, Duseja A, De A. , et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci 2018; 63 (05) 1334-1340
  CrossrefPubMedGoogle Scholar
• 56 Moini M, Ziyaeyan M, Aghaei S. , et al. Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two methods; HCV core antigen and polymerase chain reaction. Hepat Mon 2013; 13 (06) e9147
  PubMedGoogle Scholar
• 57 Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 2016; 27 (08) 2238-2246
  CrossrefPubMedGoogle Scholar
• 58 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline on the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl. In press
  PubMed
• 59 Jadoul M, Horsmans Y. Towards eradication of hepatitis C virus from dialysis units. Lancet 2015; 386 (10003): 1514-1515
  CrossrefPubMedGoogle Scholar
• 60 Platt L, Easterbrook P, Gower E. , et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16 (07) 797-808
  CrossrefPubMedGoogle Scholar
• 61 Ingiliz P, Martin TC, Rodger A. , et al; NEAT study group. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017; 66 (02) 282-287
  CrossrefPubMedGoogle Scholar
• 62 Boerekamps A, van den Berk GE, Lauw FN. , et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis 2018; 66 (09) 1360-1365
  CrossrefPubMedGoogle Scholar
• 63 Braun D, Hampel BH, Nguyen H. , et al. A Treatment as Prevention Trial to Eliminate HCV in HIV+ MSM: The Swiss HCVree Trial. Paper presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachussetts, March 4–7, 2018 [Abstract no. 81LB]. http://www.croiconference.org/sessions/treatment-prevention-trial-eliminate-hcv-hiv-msm-swiss-hcvree-trial . Accessed April 26, 2018
  PubMedGoogle Scholar
• 64 Wyles D, Bräu N, Kottilil S. , et al; ASTRAL-5 Investigators. ASTRAL-5 Investigators. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis 2017; 65 (01) 6-12
  CrossrefPubMedGoogle Scholar
• 65 Bischoff J, Mauss S, Cordes C. , et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Med 2018; 19 (04) 299-307
  CrossrefPubMedGoogle Scholar
• 66 Greenaway C, Thu Ma A, Kloda LA. , et al. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One 2015; 10 (11) e0141715
  CrossrefPubMedGoogle Scholar
• 67 Feld JJ. Extending a helping hand: addressing hepatitis C in economic migrants and refugees. Ann Hepatol 2018; 17 (01) 8-10
  CrossrefPubMedGoogle Scholar
• 68 Greenaway C, Azoulay L, Allard R. , et al. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis 2017; 17 (01) 140
  CrossrefPubMedGoogle Scholar
• 69 Sagnelli E, Alessio L, Sagnelli C. , et al. Clinical findings of HCV chronic infection in undocumented immigrants and low-income refugees in three areas of southern Italy. Ann Hepatol 2018; 17 (01) 47-53
  CrossrefPubMedGoogle Scholar
• 70 Prestileo T, Di Lorenzo F, Indovina C. , et al; Immigrant Take Care Advocacy (I.Ta.C.A.) team Palermo. Detection of HBV, HCV and HIV infection and linkage to care in migrants: the experience of the I.Ta.C.A. cohort in Palermo. Paper presented at Annual Meeting of the Italian Society of Migration Medicine; April 19, 2018; Catania, Italy
  PubMedGoogle Scholar
• 71 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018; 18 (01) 79
  CrossrefPubMedGoogle Scholar
• 72 Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49 (04) 561-573
  CrossrefPubMedGoogle Scholar
• 73 Aspinall EJ, Corson S, Doyle JS. , et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57 (Suppl. 02) S80-S89
  CrossrefPubMedGoogle Scholar
• 74 Christensen S, Buggisch P, Mauss S. , et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?. Addiction 2018; 113 (05) 868-882
  CrossrefPubMedGoogle Scholar
• 75 Ahmad F, Johnston L, Stephens B. , et al. Eradicate-C Study: Treating Chaotic Drug Users to Eliminate Hepatitis C – The Final Report. Poster presented at: International Symposium on Hepatitis Care in Substance Users; September 6–8, 2017; Jersey City, New Jersey, United States
  PubMedGoogle Scholar
• 76 Gottfreðsson M, Tyrfingsson T, Runarsdottir V. , et al. Treatment as Prevention for Hepatitis C (TraP HepC). A Real-world Experience from the First 12 Months of a Nationwide Elimination Program in Iceland. OFID 2017:4(Suppl 1):S42. [Abstract no. 1694]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632122/pdf/ofx162.101.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 77 Finessi V, Borojevic M, Messina P. , et al. Models of Care for the Management of Hepatitis C among People Who Inject Drug in Southern Switzerland: Role of Nurses. Poster presented at: International Symposium on Hepatitis Care in Substance Users; September 6-8, 2017; Jersey City, New Jersey, United States
  PubMedGoogle Scholar
• 78 Allardice K, Von Birba S, Doyle JS. , et al. Implementation of a Nurse-Led Model of Care to Treat People Who Inject Drugs (PWID) for HCV in the Community. Poster presented at: International Symposium on Hepatitis Care in Substance Users; September 6-8, 2017; Jersey City, New Jersey, United States
  PubMedGoogle Scholar
• 79 Read P, Lothian R, Chronister K. , et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 2017; 47: 209-215
  CrossrefPubMedGoogle Scholar
• 80 Olafsson S, Tyrfingsson T, Runarsdottir V. , et al. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018; 283 (05) 500-507
  CrossrefPubMedGoogle Scholar
• 81 WHO. UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users – 2012 Revision. World Health Organization. 2012. Available at: http://apps.who.int/iris/bitstream/handle/10665/77969/9789241504379_eng.pdf;jsessionid=A7DFE2BB27329EB4A29D45B1D544EAA2?sequence=1 . Accessed June 27, 2018
  PubMedGoogle Scholar
• 82 Scott N, Ólafsson S, Gottfreðsson M. , et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020. J Hepatol 2018; 68 (05) 932-939
  CrossrefPubMedGoogle Scholar
• 83 Butsashvili M. Hepatitis C Elimination Program in Georgia. Available at: https://www.eiseverywhere.com/file_uploads/6bec0fda57a3fa45db503d570d21a18d_1515FriMaiaButsashvili.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 84 Ministry of Labour, Health and Social Affairs. Strategic Plan for the Elimination of Hepatitis C Virus in Georgia, 2016–2020. Tbilisi, Georgia: Ministry of Labour, Health and Social Affairs; 2016. http://www.moh.gov.ge/uploads/files/2017/akordeoni/failebi/Georgia_HCV_Elimination_Strategy_2016-2020.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 85 ClinicalTrials.gov. Evaluating treatment as prevention among people who inject drugs in Dundee for HCV (ERAPID HCV). Available at: https://clinicaltrials.gov/ct2/show/record/NCT03356405?view=record . Accessed June 27, 2018
  PubMedGoogle Scholar
• 86 Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol 2018; 31 (01) 35-41
  PubMedGoogle Scholar
• 87 Uemura H, Tsukada K, Mizushima D. , et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. PLoS One 2017; 12 (10) e0186255
  CrossrefPubMedGoogle Scholar
• 88 Walsh CE, Workowski K, Terrault NA. , et al. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia 2017; 23 (02) 198-206
  CrossrefPubMedGoogle Scholar
• 89 Sinakos E, Kountouras D, Koskinas J. , et al. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol 2017; 178 (01) 130-136
  CrossrefPubMedGoogle Scholar
• 90 Zachou K, Arvaniti P, Gatselis NK. , et al. Patients with haemoglobinopathies and chronic hepatitis C: a real difficult to treat population in 2016?. Mediterr J Hematol Infect Dis 2017; 9 (01) e2017003
  PubMedGoogle Scholar
• 91 Department of Health. Press Release. Harris Hails Effective Eradication of Hepatitis C in Haemophilia Patients a Great Achievement for Ireland. December 22, 2016. http://health.gov.ie/blog/press-release/harris-hails-effective-eradication-of-hepatitis-c-in-haemophilia-patients-a-great-achievement-for-ireland/ . Accessed 17 April 2018
  PubMedGoogle Scholar
• 92 Matičič M, Lekše A, Kozinc M. , et al. Micro-Elimination of Hepatitis C among Patients with Congenital Bleeding Disorders in Slovenia. Slide presentation at the EASL International Liver Congress, April 11–15, 2018, Paris, France [Abstract no. THU 146]. https://ilc-congress.eu/wp-content/uploads/2018/ebooks/scientific_programme/index.html#p=192 . Accessed April 26, 2018
  PubMedGoogle Scholar
• 93 Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol 2015; 7 (21) 2323-2330
  CrossrefPubMedGoogle Scholar
• 94 Fridriksdottir RH, Fridriksdottir H, Alexiusdottir K. , et al. Outcomes of Treatment for Hepatitis C Virus Infection in the Prison Setting in the TrapHepC (Treatment as Prevention for Hepatitis C) Program in Iceland. Poster presented at: International Symposium on Hepatitis Care in Substance Users; September 6–8, 2017; Jersey City, New Jersey, United States
  PubMedGoogle Scholar
• 95 MacDonald R, Akiyama MJ, Kopolow A. , et al. Feasibility of treating hepatitis C in a transient jail population. Open Forum Infect Dis 2017; 4 (03) ofx142
  PubMedGoogle Scholar
• 96 Martin NK, Vickerman P, Brew IF. , et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology 2016; 63 (06) 1796-1808
  CrossrefPubMedGoogle Scholar
• 97 Bartlett SR, Fox P, Cabatingan H. , et al. Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project. Clin Infect Dis 2018; (e -pub ahead of print ) DOI: 10.1093/cid/ciy210.
  PubMedGoogle Scholar
• 98 Wright NMJ, Tompkins CNE, Farragher TM. Injecting drug use in prison: prevalence and implications for needle exchange policy. Int J Prison Health 2015; 11 (01) 17-29
  CrossrefPubMedGoogle Scholar
• 99 Lafferty L, Rance J, Treloar C. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug Alcohol Depend 2018; 183: 96-101
  CrossrefPubMedGoogle Scholar
• 100 Lloyd AR, Clegg J, Lange J. , et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56 (08) 1078-1084
  CrossrefPubMedGoogle Scholar
• 101 Papaluca T, McDonald L, Craigie A. , et al. Outcomes of a nurse-led model of care for HCV treatment in Victorian prisons. Slide presentation at the Australasian Viral Hepatitis Elimination Conference (AVHEC), August 10–11, 2017, Cairns, Queensland, Australia. https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/c56e6906b81344febe63b9f5f53a6743 . Accessed April 26, 2018
  PubMedGoogle Scholar
• 102 Crespo J. A Program of Testing and Treat Intended to Eliminate Hepatitis C in a Prison: The JAILFREE-C Study. AASLD Liver Learning. Nov 12, 2016; 143810. http://liverlearning.aasld.org/aasld/2016/thelivermeeting/143810/javier.crespo.a.program.of.testing.and.treat.intended.to.eliminate.hepatitis.c.html . Accessed April 26, 2018
  PubMedGoogle Scholar
• 103 Cuadrado A, Llerena S, Cobo C. , et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol 2018; DOI: 10.1038/s41395-018-0157-x. . [Epub ahead of print]
  PubMedGoogle Scholar
• 104 Beckwith CG, Kurth AE, Bazerman LB. , et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J Public Health (Oxf) 2016; 38 (01) 130-137
  CrossrefPubMedGoogle Scholar
• 105 Samur S, Kues B, Ayer T. , et al. Cost effectiveness of pre- vs post-liver transplant Hepatitis C treatment with direct-acting antivirals. Clin Gastroenterol Hepatol 2018; 16 (01) 115-122.e10
  CrossrefPubMedGoogle Scholar
• 106 Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Curr Opin Organ Transplant 2018; 23 (02) 257-263
  CrossrefPubMedGoogle Scholar
• 107 Holscher CM, Durand CM, Desai NM. Expanding the use of organs from hepatitis C-viremic donors: the evidence continues to build. Transplantation 2018; 102 (04) 546-547
  CrossrefPubMedGoogle Scholar
• 108 World Health Organization. Monitoring and Evaluation for Viral Hepatitis B and C: Recommended Indicators and Framework. Geneva:World Health Organization; 2016. http://apps.who.int/iris/bitstream/10665/204790/1/9789241510288_eng.pdf?ua=1 . Accessed May 10, 2018
  PubMedGoogle Scholar
• 109 EASL. Hepatitis C Virus Elimination Programmes Report Encouraging Results: Is Elimination Within Reach? [Public release]. https://ilc-congress.eu/wp-content/uploads/2018/04/ILC-2018-Press-Kit_FRI_SATv3.pdf . Accessed April 23, 2018
  PubMedGoogle Scholar
• 110 El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19 (44) 7880-7888
  CrossrefPubMedGoogle Scholar
• 111 Indolfi G, Hierro L, Dezsofi A. , et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66 (03) 505-515
  CrossrefPubMedGoogle Scholar
• 112 Lindsay A. Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Dublin: The Stationery Office, Government of Ireland; 2002. http://health.gov.ie/wp-content/uploads/2014/04/Tribunal-of-Inquiry-into-the-Infection-with-HIV-and-Hep-C-of-persons-with-Haemophilia-and-Related-Matters.pdf . Accessed April 26, 2018
  PubMedGoogle Scholar
• 113 Irish Haemophilia Society. Press Release. Irish Haemophilia Society Announces the Effective Eradication of Hepatitis C in People with Haemophilia in Ireland. December 22, 2016. https://haemophilia.ie/wp-content/uploads/2016/02/22-12-16-Eradication-of-Hep-C-Press-Release.pdf . Accessed 11 May 2018
  PubMedGoogle Scholar
• 114 National Hepatitis C Treatment Programme. Ireland's Health Service. https://www.hse.ie/eng/about/who/primarycare/hepcprogramme.html . Accessed April 24, 2018
  PubMedGoogle Scholar